El Roto
Viñeta de El Roto del 12 de enero de 2025
Related Articles
Navtemadlin-Based Therapy Could Drive Change in the Myelofibrosis Treatment Paradigm
John Mascarenhas, MD, discusses navtemadlin’s mechanism of action and its potential to shift the myelofibrosis treatment landscape
Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies
Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.
The role of molecular tumor boards in breast cancer care
Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, explores the critical role of molecular tumor boards (MTB) in guiding oncologists through complex…
Crunching the numbers for next-gen COVID-19 vaccines
BARDA tapped a team of Fred Hutch Cancer Center biostatisticians to determine the biomarkers that will serve as predictors of protective responses in next-generation COVID-19…
Clinicians’ knowledge and awareness of PROs in immune thrombocytopenia: results of a national survey
Esther Oliva, MD, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy, comments on a national survey conducted in Italy that investigated clinicians’ knowledge and…
As fire encroached, City of Hope prepared to evacuate its Duarte campus – The Cancer Letter
On Jan. 7, a bit after 6 p.m., Ravi Salgia was at his Eaton Canyon home, at the edge of Angeles National Forest. To access…
Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML
Olverembatinib demonstrated preliminary efficacy and was well tolerated in patients with heavily pretreated chronic-phase myeloid leukemia.
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.